Farmas USA

Amen ;-)

Guardame turno para lamer esas botas.
Un saludo y dos lametones.

Joder, qué buena pinta. Voy a ver qué cara hacen en IB. ¿Esa entrada GCT no sería mejor en diaria? Digo yo...

ODP

Beneficios 2.4 billlones frente a 2.43 esperados. Igual da buena entrada. Ayer ya bajó.

http://www.streetinsider.com/Earnings/Office+Depot%2C+Inc.+%28ODP%29+Reports+In-Line+Q2+EPS/8543551.html?si_client=intbro

ARRY, a estas horas, las posis están 6,74 x 6,85, o sea, una subida del 8-10%, tras la new de ayer del acuerdo con CELGENE y lo posislbes milestones de 380M de dólares...

IMUC, a estas horas, las posis están en 3,12 x 3,25, tras la new anunciando el inicio de Fase I en el ICT-121, en el Sinaí de los Angeles, con 20 pacientes, para el cáncer de cerebro recurrente....Van a poner una vacuna mensual, durante 4 meses....El objetivo inicial es la seguridad, y el secundario, la supervivencia global (OS) y la progresión libre de enfermedad (PFS), a los 6 meses....

Un saludo

P.D. Sigo en modo "petardo"...igual hoy recupero el valor de cartera de finales de mayo.....

ImmunoCellular Therapeutics Announces Initiation of Phase I Trial of Cancer Vaccine ICT-121 in Recurrent Glioblastoma
Date : 07/30/2013 @ 6:00AM
Source : Business Wire
Stock : Immunocellular Therapeutics, Ltd. (IMUC)
Quote : 3.08 0.0 (0.00%) @ 7:11AM
ImmunoCellular Therapeutics Announces Initiation of Phase I Trial of Cancer Vaccine ICT-121 in Recurrent Glioblastoma
Print
Immunocellular Therapeutics, Ltd. (AMEX:IMUC)
Intraday Stock Chart
Today : Tuesday 30 July 2013

Click Here for more Immunocellular Therapeutics, Ltd. Charts.
ImmunoCellular Therapeutics, Ltd. (“ImmunoCellular”) (NYSE MKT: IMUC) today announced initiation of a phase I clinical trial of cancer vaccine ICT-121 as a potential treatment for patients with recurrent glioblastoma multiforme (GBM). The investigator-sponsored phase I trial is being conducted at Cedars-Sinai Medical Center in Los Angeles, CA, by Jeremy Rudnick, MD, and ImmunoCellular is supporting the trial by providing the ICT-121 vaccine. ICT-121 is a dendritic cell vaccine targeting CD133, an important cancer stem cell marker that is commonly overexpressed on a broad range of solid tumors.

The primary objective of the open label phase I trial is to assess the safety and tolerability of ICT-121. Secondary objectives include overall survival (OS) and progression-free survival (PFS) at six months after surgery as well as other response parameters. Approximately 20 patients who have had gross tumor resection and experience a first recurrence of GBM, and who are HLA-A2 positive, will be treated in the trial. Patients will be administered the vaccine once per week for four weeks during the induction phase, followed by a maintenance phase consisting of one treatment every two months until their supply of vaccine is depleted or they experience progressive disease.

“The initiation of the ICT-121 trial completes another important clinical milestone for ImmunoCellular and adds to the substantial pipeline progress we have made this year in advancing our ICT-107 phase II program in patients with newly diagnosed brain cancer,” said Andrew Gengos, ImmunoCellular Chief Executive Officer. “We are positioning our company as an emerging leader in cancer immunotherapy by building our dendritic cell-based vaccine pipeline, maintaining a strong financial underpinning, and planning for the future should we achieve success in our ongoing ICT-107 phase II trial. The second half of 2013 will be an exciting time as we expect to reach the prescribed event level in the ICT-107 trial that triggers analysis of the final results.”

Earlier this year, ImmunoCellular announced that the US Patent and Trademark Office (USPTO) issued a key patent application covering ICT-121. The patent includes claims covering composition of matter as well as methods of use. Specifically, the claims encompass immunogens comprising a CD133 epitope and variants thereof as well as methods of using such immunogens in immunization and to elicit cytotoxic T lymphocyte responses that are specific for tumor cells expressing the HLA-A2 antigen.

yo he puesto orden de cerrar unos largos en 7.55, y abrir cortos en ese mismo precio.
orden del dia, que no seria la primera vez que la pongo GTC y se me ejecuta algun dia despues por capullo.
snta

reviso siempre las ordens abiertas tras el cierre , no se me escapara.
De todos modos si que es mejor ponerlo para el dia en curso.
Bueno, veo que os animais. Habra que dejarl correr la primera media hora o asi para ver hasta donde la suben.
Los 7,5x de Emilio para ir corto seria cojonudo.
SNTA

Buenos dias...
A mi no me deja entrar la orden "sell short"...
Me dice que no puedo hacerlo hoy para este valor...

Un saludo

SNTA